In This Article:
Growth is oxygen. But when it evaporates, the consequences can be extreme - ask anyone who bought Cisco in the Dot-Com Bubble (Nvidia?) or newer investors who lived through the 2020 to 2022 COVID cycle.
The risks that can come from buying these assets is precisely why we started StockStory - to isolate the long-term winners from the losers so you can invest with confidence. Keeping that in mind, here is one growth stock expanding its competitive advantage and two climbing an uphill battle.
Two Growth Stocks to Sell:
SoundHound AI (SOUN)
One-Year Revenue Growth: +101%
Founded in 2005, SoundHound AI (NASDAQ:SOUN) develops independent voice artificial intelligence solutions that enable businesses across various industries to offer customized conversational experiences to consumers.
Why Is SOUN Not Exciting?
-
Sky-high servicing costs result in an inferior gross margin of 44.1% that must be offset through increased usage
-
Operating margin fell by 39 percentage points over the last year as it prioritized growth over profits
-
Cash-burning tendencies make us wonder if it can sustainably generate shareholder value
At $9.55 per share, SoundHound AI trades at 25.4x forward price-to-sales. Check out our free in-depth research report to learn more about why SOUN doesn’t pass our bar.
Corcept (CORT)
One-Year Revenue Growth: +30.9%
Focusing on the powerful stress hormone that affects everything from metabolism to immune function, Corcept Therapeutics (NASDAQ:CORT) develops and markets medications that modulate cortisol to treat endocrine disorders, cancer, and neurological diseases.
Why Are We Hesitant About CORT?
-
Revenue base of $685.4 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
-
Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 16.2 percentage points
-
16.1 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
Corcept is trading at $78.01 per share, or 39x forward P/E. Read our free research report to see why you should think twice about including CORT in your portfolio, it’s free.
One Growth Stock to Watch:
Option Care Health (OPCH)
One-Year Revenue Growth: +17%
With a nationwide network of 177 locations serving 43 states and a team of over 4,500 clinicians, Option Care Health (NASDAQ:OPCH) is the largest independent provider of home and alternate site infusion services, delivering medications and clinical support to patients across the United States.